Double-blind placebo-controlled trial of flunarizine as add-on therapy in epilepsy. 1984

J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier

In a therapy-resistant epileptic population with partial complex seizures with or without secondary generalization, addition of flunarizine to existing therapy was accompanied by a significant reduction in complex partial and tonic-clonic seizures. This result did not appear to be due to serial effects or changes in the plasma levels of the co-medication. Side effects were rare. The serum flunarizine levels (13.8 ng/ml; range, 3-32.5 ng/ml) were lower than previously reported on a daily dose of 10 mg. This may reflect increased metabolism due to induction of liver enzymes by the co-medication. Given this finding, together with the low incidence of side effects, a further study is required to determine whether higher blood levels would give an improved degree and incidence of seizure reduction.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010879 Piperazines Compounds that are derived from PIPERAZINE.
D002936 Cinnarizine A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS. 1-(Diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine,Cinarizina Inkey,Cinarizina Ratiopharm,Cinarizine,Cinazière,Cinna,Cinnarizin AL,Cinnarizin Siegfried,Cinnarizin Von Ct,Cinnarizin-Ratiopharm,Cinnarizine L-Tartrate,Cinnarizine L-Tartrate (1:1),Cinnarizine, (E)-Isomer,Cinnarizine, Dihydrochloride,Cinnipirine,Cisaken,Dimitronal,R-516,Stugeron,Stugeron Forte,Cinnarizin Ratiopharm,Cinnarizine L Tartrate,Dihydrochloride Cinnarizine,L-Tartrate, Cinnarizine,R 516,R516,Von Ct, Cinnarizin
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D005444 Flunarizine Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy. Flunarizin,Flunarizine Dihydrochloride,Flunarizine Hydrochloride,R-14950,Sibelium,Dihydrochloride, Flunarizine,Hydrochloride, Flunarizine,R 14950,R14950
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
July 1991, Brain & development,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
January 1996, Brain & development,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
January 1994, Epilepsia,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
January 1986, Functional neurology,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
June 1988, Clinical neuropharmacology,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
February 1989, Acta neurologica Scandinavica,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
January 1994, Epilepsia,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
January 1991, Epilepsia,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
May 1989, The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques,
J Overweg, and C D Binnie, and J W Meijer, and H Meinardi, and S T Nuijten, and S Schmaltz, and A Wauquier
August 1990, Epilepsy research,
Copied contents to your clipboard!